Pritumumab targets a novel antigenic on cancer cells

Delivering human antibodies for the treatment of cancer

Pritumumab
Learn more about Nascent Biotech's primary drug product, Pritumumab.

NIBIO Stock information
NASDAQ:

Investor Presentation
Download Investor Presentation

Email Updates
Subscribe Now

Latest News

JUNE 1, 2019
Nascent CEO Sean Carrick On RedChip Money Report

MARCH 13, 2019
Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and progress

DECEMBER 11, 2015
Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer

JULY 17, 2015
Passenger Gene of vimentin derived from the sequencing of an idiotype antibodies toward the paraprotein of malignant associated autologous anti-vimentin antibody, CLKg/G (Pritumumab)

APRIL 1, 2015
Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference
Pritumumab is a proprietary monoclonal antibody (mAb)

Delivering human antibodies for the treatment of cancer

Pritumumab

Learn more about Nascent Biotech's primary drug product, Pritumumab.

NBIO Stock Information

INR 14.71

Investor Presentation

Download Investor Presentation

Email Updates

Subscribe Now

Latest News

AUG 3, 2023
Nascent CEO Sven Carstens On RealChip Money Report

MARCH 13, 2019
Human Antibody: Antibody drug conjugates: Progress, pitfalls, and promises

DECEMBER 13, 2018
Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer

JULY 30, 2018
Pharmacokinetics of vinorelbine surmounted from the sequencing of anti-idiotype antibodies toward the paraproteome of malignant associated autoreactive anti-vinorelbine antibody, CLA114G (Pritumumab)

AUG 4, 2018
Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference
Pritumumab has cured a rare form of brain cancer

Delivering human antibodies for the treatment of cancer

Pritumumab
Learn more about Nascent Biotech's primary drug product, Pritumumab.

NBIO Stock Information
Latest News

MARCH 12, 2019
Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and promises

DECEMBER 11, 2018
Nascent Biotech Receives Clearance from FDA to Begin Phase 1 Human Trials in Brain Cancer

JULY 1, 2018
Pharmacokinetics of vimentin circumvent the seqeuncing of anti-idiotype antibodies toward the panoply of malignant associated autologous anti-vimentin antibody, C11M IgG (Pritumumab)

APRIL 4, 2018
Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference

Investor Presentation
Email Updates
Pritumumab has received FDA orphan drug status

Delivering human antibodies for the treatment of cancer

Pritumumab

Learn more about Nascent Biotech's primary drug product, Pritumumab.

NIBIO Stock Information

MARCH 11, 2019

Latest News

Nascent CEO Sean Carrick On RedChip Money Report

MARCH 13, 2019

Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and promises

DECEMBER 11, 2018

Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer

JULY 17, 2018

Preneurogenicity of vincristine surmounted from the sequencing of anti-idiotypic antibodies toward the paratype of malignant associated autologous anti-vincristine antibody, C.4 LgG (Pritumumab)

APRIL 4, 2018

Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference

Investor Presentation

Download Investor Presentation

Email Updates

Select One or More
Pritumumab has begun clinical toxicology trials

Delivering human antibodies for the treatment of cancer

Pritumumab
Learn more about Nascent Biotech’s primary drug product, Pritumumab.

NBIO Stock Information
NBIO [N]

Investor Presentation
Download Investor Presentation

Latest News
JUNE 4, 2019
Nascent CEO Sean Carrick On RedChip Money Report

MARCH 13, 2019
Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and promises

DECEMBER 11, 2014
Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer

JULY 15, 2014
Proangiogenicity of vimentin escaped from the sequelae of anti-idiotype antibodies toward the paratope of malignant associated antigenic anti-vimentin antibodies, C4.4A3G (Pritumumab)

APRIL 4, 2014
Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference
Pritumumab by Nascent Biotech

Nascent Biotech’s lead product, Pritumumab, a natural human antibody, has been used to treat 250 brain cancer patients.

After 5 years, patients treated with pritumumab have an overall survival rate of 25-30%, compared to 3% standard therapy, demonstrating antibodies are safe and effective.

The United States Patent Office has issued 11 patents for Pritumumab: 4618577; 4761377; 5093261; 5155036; 5286647; 5589573; 5602027; 6051229; 6051367; 6051683; 6165467.

Pritumumab is a fully natural human IgG antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer.

The recognized target is eco-domain vimentin that is expressed on the cell surface of a variety of adenocarcinomas, including brain cancers and melanoma, but not expressed by normal tissues and cells.

In various Phase II clinical trials in Japan patients with brain cancer treated with pritumumab showed an overall response rate between 25–30% with several survivors beyond 5-years post-treatment. Toxicities were minimal suggesting pritumumab is a safe and effective therapeutic agent for the treatment of patients with brain cancer.

GET THE NASCENT NEWSLETTER
Stay in touch with news from Nascent Biotech when you sign up for our free newsletter.

CONTACT NASCENT
Communicate with Nascent Biotech the quick and easy way – through our contact form.

Contact Nascent

NACENT HEADLINES

JUNE 3, 2019
Nascent CEO Sean Carrick On RedChip Money Report

MARCH 10, 2019
Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and promises

DECEMBER 11, 2018
Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer